Modality
Gene Editing
MOA
PI3Ki
Target
LAG-3
Pathway
Apoptosis
OCDParkinson's
Development Pipeline
Preclinical
~Sep 2017
→ ~Dec 2018
Phase 1
~Mar 2019
→ ~Jun 2020
Phase 2
Sep 2020
→ Nov 2027
Phase 2Current
NCT04909509
1,701 pts·Parkinson's
2022-08→2027-11·Active
NCT07787367
1,391 pts·OCD
2020-09→2026-10·Active
3,092 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-10-197mo awayPh2 Data· OCD
2027-11-041.6y awayPh2 Data· Parkinson's
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2
Active
P2
Active
Catalysts
Ph2 Data
2026-10-19 · 7mo away
OCD
Ph2 Data
2027-11-04 · 1.6y away
Parkinson's
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04909509 | Phase 2 | Parkinson's | Active | 1701 | EFS |
| NCT07787367 | Phase 2 | OCD | Active | 1391 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 |